News | 19 February 2021
Dr. Reddy's Laboratories launches FH Tablets in the U.S. Market
Fluphenazine Hydrochloride Tablets, USP are available in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.
Fluphenazine Hydrochloride Tablets, USP are available in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.
Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).
posaconazole delayed-release tablets 100 mg are the generic equivalent of Noxafil.
India business grew 11.8% YoY vs mid-single digit industry growth.
The jump in profit is due to the better performance of the API business.
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
According to IQVIA sales data for the 12 month period ending December 2020, the Cleocin T Gel, 1% market achieved annual sales of approximately $73.8 million.
Be One is a 100% Ayurvedic health and wellness supplement.
.jpg)
Indian Chemical News, an online news media covering Pharma, Chemical and Petrochemical sector is organizing an E-conference on “India's Pharma Industry Outlook 2021” on 12th February, 2021 from 3:00 PM – 4:30 PM.
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
Tavaborole Topical Solution, 5%, is an oxaborole antifungal.
The company posted net profit of Rs.203.38 crores for the period ended December 31, 2019.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
Subscribe To Our Newsletter & Stay Updated
